.svg)
A delegation from Alexion – the medical arm for rare disease treatment of the global company AstraZeneca – visited “Masri” Medical Research Center at the Faculty of Medicine
As part of strengthening strategic cooperation to improve and advance healthcare for patients with rare diseases in the Arab Republic of Egypt, and under the patronage of Prof. Mohamed Diaa El-Din Zain El-Abedeen, President of Ain Shams University, Prof. Ali Al-Anwar, Dean of the Faculty of Medicine and Chairman of the University Hospitals Board, Prof. Hesham El-Ghazaly, Director of the MASRI Clinical Research Center, and Prof. Fatma Obeid, Director of the Clinical Research Center, the MASRI Clinical Research Center (MASRI-CRC) hosted this week a high-level delegation from Alexion, the rare disease treatment arm of the global company AstraZeneca.
The delegation included: Dr. Patrick Mikoski, Vice President for Global Clinical Research; Dr. Ahmed Hegazy, Director of Middle East Markets; Dr. Thomas Labib, Medical Director for Rare Diseases, Egypt; and Dr. Ahmed Abou Taleb, Director of Research, Egypt.
The visit was in line with Egypt’s national efforts and reaffirmed its pioneering role in supporting public health issues, crowned by its sponsorship of the historic resolution on rare diseases during the World Health Assembly last May.
Discussions focused on ways to strengthen the partnership between both parties in developing healthcare infrastructure, driving innovation in medical research, and exchanging expertise to build research capacity, thereby supporting the achievement of Egypt’s Health Vision 2030.
The visit program included a comprehensive presentation delivered by Prof. Fatma Obeid, Director of the Clinical Research Center, showcasing the center’s advanced technical and scientific capabilities as well as its research achievements, followed by a tour of the center’s state-of-the-art facilities. The delegation also met with Prof. Hesham El-Ghazaly, Director of the MASRI Research Center, to discuss prospects for future cooperation and to set executive plans aimed at achieving a qualitative leap in the services provided to rare disease patients.
The delegation expressed pride in its ongoing strategic partnership with the Egyptian state and its health institutions, affirming AstraZeneca’s commitment to working hand in hand with health authorities and research centers in Egypt to deliver the best possible care to Egyptian patients.
